tiprankstipranks
Blurbs

Analysts Are Bullish on Top Healthcare Stocks: UnitedHealth (UNH), Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on UnitedHealth (UNHResearch Report), Ultragenyx Pharmaceutical (RAREResearch Report) and Lantheus (LNTHResearch Report) with bullish sentiments.

UnitedHealth (UNH)

Mizuho Securities analyst Ann Hynes reiterated a Buy rating on UnitedHealth on July 15 and set a price target of $550.00. The company’s shares closed last Tuesday at $533.45, close to its 52-week high of $553.29.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 8.4% and a 57.2% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, AmerisourceBergen, and Molina Healthcare.

UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $581.67, implying an 11.6% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a $556.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ultragenyx Pharmaceutical (RARE)

In a report issued on July 18, Joseph Schwartz from SVB Securities reiterated a Buy rating on Ultragenyx Pharmaceutical, with a price target of $115.00. The company’s shares closed last Tuesday at $52.89, close to its 52-week low of $45.20.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.0% and a 36.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $108.60 average price target, implying a 94.1% upside from current levels. In a report issued on July 14, Truist Financial also reiterated a Buy rating on the stock with a $185.00 price target.

Lantheus (LNTH)

In a report issued on July 18, Roanna Ruiz from SVB Securities reiterated a Buy rating on Lantheus, with a price target of $100.00. The company’s shares closed last Tuesday at $71.48, close to its 52-week high of $73.78.

According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -57.8% and a 5.9% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $95.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UNH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed